Julia Wermerskirchen , PharmD, former co-founder and Vice President of Payer and Provider Relations at Optum Frontier Therapies, Joins Precision AQ NEW YORK , March 24, 2025 /PRNewswire/ -- Precision AQ, a leader in life sciences commercialization and a driving force in expanding patient access to life-changing therapies, announces the addition of Julia Wermerskirchen , PharmD, to its AET. Wermerskirchen is a recognized authority in rare disease access strategy, with specialized expertise in payer negotiations, specialty pharmacy strategy, and reimbursement policy. Her extensive experience in evaluating coverage and access for high-cost therapies will enable life sciences companies to effectively navigate payer scrutiny, evolving policy frameworks, and access challenges.
As the rare disease sector continues to expand at an unprecedented pace, the addition of Wermerskirchen further reinforces Precision AQ's capabilities in addressing the increasing complexities of rare and orphan disease market access. In 2024, more than half of all novel therapies approved by the FDA targeted rare diseases, extending a two-decade trend of increased orphan drug approvals. This rapid growth has intensified payer scrutiny, driving greater demand for comprehensive clinical and economic evidence and leading to stricter reimbursement policies.
To navigate this evolving landscape, manufacturers must adopt proactive, data-driven strategies that ensure sustained access to innovative treatments while a.
